Atara biotherapeutics to announce second quarter 2021 financial results on monday, august 9, 2021
South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the company will release second quarter 2021 financial results after market close on monday, august 9, 2021. following the release, the company will host a live conference call and webcast at 4:30 p.m. edt to discuss the company’s financial results and provide a corporate update. analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference id 13720150. a live audio webcast can be accessed by visiting the investors & media – news & events section of atarabio.com. an archived replay will be available on the company's website for 30 days following the live webcast. about atara biotherapeutics, inc. atara biotherapeutics, inc. (@atarabio) is a pioneer in t-cell immunotherapy leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. with our lead program in phase 3 clinical development, atara is the most advanced allogeneic t-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. our platform leverages the unique biology of ebv t cells and has the capability to treat a wide range of ebv-associated diseases, or other serious diseases through incorporation of engineered cars (chimeric antigen receptors) or tcrs (t-cell receptors). atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in phase 3 development for epstein-barr virus-driven post-transplant lymphoproliferative disease (ebv+ ptld); ata188, a t-cell immunotherapy targeting ebv antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor t-cell (car t) immunotherapies for both solid tumors and hematologic malignancies. improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. atara is headquartered in south san francisco and our leading-edge research, development and manufacturing facility is based in thousand oaks, california. for additional information about the company, please visit atarabio.com and follow us on twitter and linkedin.
ATRA Ratings Summary
ATRA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission